Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISLE-HFpEF: Intravenous Iron in HFpEF With Iron Deficiency
NCT07643818Phase 2Enrolling by invitation
- Sponsor
- Government of Jersey
- Start
- Jun 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of ferric derisomaltose in heart failure with preserved ejection fraction (HFpEF), iron deficiency anemia (IDA), sponsored by Government of Jersey. Started Jun 2026; status: enrolling by invitation.
02
Drugs
ferric derisomaltose
03
Conditions
heart failure with preserved ejection fraction (HFpEF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT07643818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643818.